Viatris Inc.
VTRS
株式のランク
#1100
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its... Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
株価
$18.50
時価総額
$21.24B
変化（1日）
1.29%
変化（1年）
79.39%
国
US
取引 Viatris Inc. (VTRS)
カテゴリー
Healthcare
Viatris Inc.（VTRS）のP/E比率
October 2026 時点のP/E比率 TTM -48.44
Viatris Inc. の最新の財務報告および株価によると、現在の P/E (TTM) は -48.44 です。2023 年末時点での P/E は 237.65 でした。
Viatris Inc. の P/E 比率の履歴（2004 〜 2026）
各年末のP/E比率
| 年 | P/E比率 | 変化 |
|---|---|---|
| 2026 (TTM) | -48.44 | 106.76% |
| 2024 | -23.43 | -109.86% |
| 2023 | 237.65 | 3,561.56% |
| 2022 | 6.49 | -150.36% |
| 2021 | -12.89 | -23.37% |
| 2020 | -16.82 | -102.51% |
| 2019 | 670.00 | 1,568.83% |
| 2018 | 40.15 | 23.36% |
| 2017 | 32.55 | -21.33% |
| 2016 | 41.37 | 30.38% |
| 2015 | 31.73 | 31.72% |
| 2014 | 24.09 | -12.25% |
| 2013 | 27.45 | 54.35% |
| 2012 | 17.79 | 3.26% |
| 2011 | 17.22 | -13.30% |
| 2010 | 19.86 | -17.85% |
| 2009 | 24.18 | -257.52% |
| 2008 | -15.35 | 544.28% |
| 2007 | -2.38 | -108.19% |
| 2006 | 29.09 | 24.24% |
| 2005 | 23.41 | 28.15% |
| 2004 | 18.27 | 0.00% |
類似企業や競合他社のP/E比率
| 企業 | P/E比率 | P/E比率の差 | 国 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | -172.16% |
IN
|
P/E比率の読み方
株価収益率（P/E Ratio）は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の（0に近い）P/Eは、損失が大きいことを示します。
P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。
10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。